TY  - GEN
AU  - Conteduca, Vincenza
AU  - Jayaram, Anuradha
AU  - Romero-Laorden, Nuria
AU  - Wetterskog, Daniel
AU  - Salvi, Samanta
AU  - Gurioli, Giorgia
AU  - Scarpi, Emanuela
AU  - Castro, Elena
AU  - Marin-Aguilera, Mercedes
AU  - Lolli, Cristian
AU  - Schepisi, Giuseppe
AU  - Maugeri, Antonio
AU  - Wingate, Anna
AU  - Farolfi, Alberto
AU  - Casadio, Valentina
AU  - Medina, Ana
AU  - Puente, Javier
AU  - Mendez Vidal, María Jose
AU  - Morales-Barrera, Rafael
AU  - Villa-Guzman, Jose C
AU  - Hernando Polo, Susana
AU  - Rodriguez-Vida, Alejo
AU  - Gonzalez-del-Alba, Aranzazu
AU  - Mellado, Begona
AU  - Gonzalez-Billalabeitia, Enrique
AU  - Olmos, David
AU  - Attard, Gerhardt
AU  - De Giorgi, Ugo
PY  - 2019
DO  - 10.1016/j.eururo.2018.09.049
SN  - 0302-2838
UR  - https://hdl.handle.net/20.500.12105/22692
AB  - Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate...
LA  - eng
PB  - Elsevier
KW  - Castration-resistant prostate cancer
KW  - Androgen receptor
KW  - Plasma DNA
KW  - Docetaxel
KW  - Androgen receptor-directed therapies
KW  - Biomarker
KW  - Prostate-Specific Antigen
KW  - Androgen Antagonists
KW  - Androstenes
KW  - Spain
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Kallikreins
KW  - Progression-Free Survival
KW  - Antineoplastic Agents
KW  - Docetaxel
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Male
KW  - Time Factors
KW  - Receptors, Androgen
KW  - Neoplasm Metastasis
KW  - Phenylthiohydantoin
TI  - Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
TY  - research article
ER  -